JPWO2020214728A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020214728A5
JPWO2020214728A5 JP2021561813A JP2021561813A JPWO2020214728A5 JP WO2020214728 A5 JPWO2020214728 A5 JP WO2020214728A5 JP 2021561813 A JP2021561813 A JP 2021561813A JP 2021561813 A JP2021561813 A JP 2021561813A JP WO2020214728 A5 JPWO2020214728 A5 JP WO2020214728A5
Authority
JP
Japan
Prior art keywords
optionally substituted
unsubstituted
alkyl
heterocyclyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021561813A
Other languages
English (en)
Japanese (ja)
Other versions
JP7381602B2 (ja
JP2022529466A5 (https=
JP2022529466A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/028349 external-priority patent/WO2020214728A1/en
Publication of JP2022529466A publication Critical patent/JP2022529466A/ja
Publication of JPWO2020214728A5 publication Critical patent/JPWO2020214728A5/ja
Publication of JP2022529466A5 publication Critical patent/JP2022529466A5/ja
Application granted granted Critical
Publication of JP7381602B2 publication Critical patent/JP7381602B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021561813A 2019-04-17 2020-04-15 二環式及び三環式化合物 Active JP7381602B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962835301P 2019-04-17 2019-04-17
US62/835,301 2019-04-17
PCT/US2020/028349 WO2020214728A1 (en) 2019-04-17 2020-04-15 Bicyclic and tricyclic compounds

Publications (4)

Publication Number Publication Date
JP2022529466A JP2022529466A (ja) 2022-06-22
JPWO2020214728A5 true JPWO2020214728A5 (https=) 2023-04-24
JP2022529466A5 JP2022529466A5 (https=) 2023-04-24
JP7381602B2 JP7381602B2 (ja) 2023-11-15

Family

ID=72838352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021561813A Active JP7381602B2 (ja) 2019-04-17 2020-04-15 二環式及び三環式化合物

Country Status (9)

Country Link
US (1) US11591341B2 (https=)
EP (1) EP3956331A4 (https=)
JP (1) JP7381602B2 (https=)
KR (1) KR102641566B1 (https=)
CN (1) CN113939513A (https=)
AU (1) AU2020260105A1 (https=)
CA (1) CA3136603A1 (https=)
TW (1) TWI819213B (https=)
WO (1) WO2020214728A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4229062A4 (en) * 2020-10-15 2024-10-30 Aligos Therapeutics, Inc. Bicyclic compounds
CN114478536B (zh) * 2020-10-28 2024-12-13 上海森辉医药有限公司 四氢吡嗪稠环衍生物的制备方法
CA3231695A1 (en) 2021-09-08 2023-03-16 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
WO2023205645A1 (en) 2022-04-20 2023-10-26 Aligos Therapeutics, Inc. Bicyclic compounds
WO2024228401A1 (ja) * 2023-05-02 2024-11-07 国立大学法人 大分大学 新型コロナウイルス感染症の処置または予防用医薬としての置換三環式複素環化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256357A1 (en) * 2006-08-09 2010-10-07 Agouron Pharmaceuticals, Inc. Heterocycles useful as inhibitors of carbonic anhydrase
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
WO2016168633A1 (en) * 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
US10179131B2 (en) * 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CN110066278B (zh) 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
PE20211783A1 (es) 2018-11-08 2021-09-08 Aligos Therapeutics Inc Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos
EP4229062A4 (en) 2020-10-15 2024-10-30 Aligos Therapeutics, Inc. Bicyclic compounds

Similar Documents

Publication Publication Date Title
JP2015526448A5 (https=)
JP2020505395A5 (https=)
ES2606630T3 (es) Derivados de trifluorometil-oxadiazol novedosos y su uso en el tratamiento de enfermedad
JP2010514768A5 (https=)
JP2022501430A5 (https=)
JP2014520822A5 (https=)
JP2021501756A5 (https=)
WO2017001853A1 (en) Antiviral compounds
RU2006134003A (ru) Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
WO2018013597A4 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
JP2007517035A5 (https=)
BRPI0614654A2 (pt) inibidores macrocìclicos de vìrus de hepatite c
US20160115149A1 (en) Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
RU2017145650A (ru) Ингибиторы тирозинкиназы брутона
JP2007532479A5 (https=)
RU2008152171A (ru) Новые ингибиторы вирусной репликации гепатита с
JP2019509288A (ja) 非環状抗ウイルス 優先出願の参照による組み込み
JPWO2021060453A5 (https=)
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
CN114258391A (zh) 吡咯化合物
JP2005526794A5 (ja) ベンズイミダゾールおよびマイトジェン活性化およびrhoキナーゼ阻害剤としてのその使用
HUP0200447A2 (en) Ribavirin-interferon alfa combination theory for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
CN112469716B (zh) 二氢嘧啶衍生物及其用途
RU2007118729A (ru) Пуриновые производные для применения в качестве агонистов аденозинового рецептора а-2а
JPWO2020214728A5 (https=)